ImmuCell reports 11.5% Q2 2026 sales growth, driven by domestic demand

ImmuCell Corporation announced preliminary, unaudited sales results for the second quarter of 2026 on July 9, 2026. Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the same period in 2025, driven by a 27.7% increase in domestic sales.¹

Chief Financial Officer Timothy Fiori noted that the comparison was complicated by prior-year dynamics. The company said the quarter's growth was significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders.¹ International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9%, compared to 2025, though the company said it believes end-customer demand remains strong, particularly in Canada.¹

Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025.¹

President and CEO Olivier te Boekhorst attributed the results to product availability and demand. He said the company achieved another strong sales quarter, supported by product availability and demand in the U.S., and that during the quarter the company directed commercial efforts toward year-round dairy customers.¹ This more price-sensitive segment generated demand resulting in 23.8% growth of Dual-Force® and 8.3% growth of Tri-Shield First Defense® within that customer group, according to the company.¹ The company said the expansion of its commercial team is contributing to increased customer acquisitions in that segment.¹

ImmuCell plans to hold a conference call to discuss full financial results. Management said it looks forward to discussing revenue drivers and complete financial results on a conference call on Friday, August 14, 2026 at 9:00 AM ET.¹